Literature DB >> 20408969

Different cytokine profile and eosinophil activation are involved in rhinovirus- and RS virus-induced acute exacerbation of childhood wheezing.

Masahiko Kato1, Hiroyuki Tsukagoshi, Masakazu Yoshizumi, Mika Saitoh, Kunihisa Kozawa, Yoshiyuki Yamada, Kenichi Maruyama, Yasuhide Hayashi, Hirokazu Kimura.   

Abstract

Because little information is available on eosinophil activation and cytokine response in virus-induced wheezing, we attempted to detect respiratory viruses and measure eosinophil cationic protein (ECP), and 27 types of cytokines/chemokines in both serum and nasal secretions from children with wheezing. This study was an observational, case-control investigation of 267 subjects, who were visited and/or hospitalized with acute respiratory symptoms (with wheezing: men, 115; women, 59; mean/median age, 3.6/3.0 years) or who were visited for regular physical examination and treatment (non-symptomatic wheezing: men, 48; women, 31; mean/median, 5.0/4.7 years), and 14 control subjects (controls: men, 9; women, 5; mean/median, 3.6/3.7 years). We detected viruses in nasal secretions from 174 patients with acute exacerbations of wheezing using antigen detection kits or reverse transcription-polymerase chain reaction, followed by direct DNA sequencing analysis. We measured peripheral eosinophil counts, and serum concentrations of ECP and 27 cytokines/chemokines using a multiplex bead-based assay in patients with wheezing or non-symptomatic wheezing. We also examined nasal ECP and 27 cytokines/chemokines in patients with wheezing. Of 174 samples from wheezing exacerbations, rhinovirus was detected in 59; respiratory syncytial (RS) virus in 44; enterovirus in 17; other viruses in 19; and no viruses in 35. Serum concentrations of ECP, IL-5, IL-6, IL-1ra, and IP-10 were significantly elevated in rhinovirus-induced wheezing compared with non-symptomatic wheezing. Similarly, serum ECP, IL-5, and IP-10 were significantly higher in rhinovirus-induced wheezing than in controls. On the other hand, IL-1ra and IP-10, but not ECP and IL-5 were significantly higher in RS virus-induced wheezing than in controls. Furthermore, only IL-5 was significantly elevated in the rhinovirus group compared with the RS virus group in both serum and nasal secretions. Different cytokine profile and eosinophil activation might be involved in rhinovirus- and RS virus-induced acute exacerbation of childhood wheezing.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20408969     DOI: 10.1111/j.1399-3038.2010.01026.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  16 in total

1.  Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze.

Authors:  Kedir N Turi; Jyoti Shankar; Larry J Anderson; Devi Rajan; Kelsey Gaston; Tebeb Gebretsadik; Suman R Das; Cosby Stone; Emma K Larkin; Christian Rosas-Salazar; Steven M Brunwasser; Martin L Moore; R Stokes Peebles; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2018-10-15       Impact factor: 21.405

2.  A molecular epidemiological study of respiratory viruses detected in Japanese children with acute wheezing illness.

Authors:  Asako Fujitsuka; Hiroyuki Tsukagoshi; Mika Arakawa; Kazuko Goto-Sugai; Akihide Ryo; Yoshimichi Okayama; Katsumi Mizuta; Atsuyoshi Nishina; Masakazu Yoshizumi; Yoichi Kaburagi; Masahiro Noda; Masato Tashiro; Nobuhiko Okabe; Masaaki Mori; Shumpei Yokota; Hirokazu Kimura
Journal:  BMC Infect Dis       Date:  2011-06-10       Impact factor: 3.090

3.  Expression of SCGB1C1 gene as a potential marker of susceptibility to upper respiratory tract infections in elite athletes - a pilot study.

Authors:  J Orysiak; J Malczewska-Lenczowska; M Bik-Multanowski
Journal:  Biol Sport       Date:  2016-03-06       Impact factor: 2.806

4.  Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults.

Authors:  Mary S Hayney; Kelsey M Henriquez; Jodi H Barnet; Tola Ewers; Heather M Champion; Sean Flannery; Bruce Barrett
Journal:  J Clin Virol       Date:  2017-03-16       Impact factor: 3.168

5.  Asthma exacerbations in a subtropical area and the role of respiratory viruses: a cross-sectional study.

Authors:  Lusmaia Damaceno Camargo Costa; Paulo Augusto Moreira Camargos; Paul L P Brand; Fabíola Souza Fiaccadori; Menira Borges de Lima Dias E Souza; Divina das Dôres de Paula Cardoso; Ítalo de Araújo Castro; Ruth Minamisava; Paulo Sérgio Sucasas da Costa
Journal:  BMC Pulm Med       Date:  2018-07-03       Impact factor: 3.317

6.  The association between blood eosinophil percent and bacterial infection in acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Juwhan Choi; Jee Youn Oh; Young Seok Lee; Gyu Young Hur; Sung Yong Lee; Jae Jeong Shim; Kyung Ho Kang; Kyung Hoon Min
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-06

7.  Clinical and Th1/Th2 immune response features of hospitalized children with human rhinovirus infection.

Authors:  Xin-Hui Yuan; Yu-Mei Li; Yi-Yi Shen; Jin Yang; Yu Jin
Journal:  J Med Virol       Date:  2019-09-18       Impact factor: 2.327

Review 8.  Molecular epidemiology of respiratory viruses in virus-induced asthma.

Authors:  Hiroyuki Tsukagoshi; Taisei Ishioka; Masahiro Noda; Kunihisa Kozawa; Hirokazu Kimura
Journal:  Front Microbiol       Date:  2013-09-12       Impact factor: 5.640

Review 9.  Cytokine production and signaling pathways in respiratory virus infection.

Authors:  Hirokazu Kimura; Masakazu Yoshizumi; Haruyuki Ishii; Kazunori Oishi; Akihide Ryo
Journal:  Front Microbiol       Date:  2013-09-17       Impact factor: 5.640

10.  Prevalence of respiratory viral infection in children hospitalized for acute lower respiratory tract diseases, and association of rhinovirus and influenza virus with asthma exacerbations.

Authors:  Jang-Mi Kwon; Jae Won Shim; Deok Soo Kim; Hye Lim Jung; Moon Soo Park; Jung Yeon Shim
Journal:  Korean J Pediatr       Date:  2014-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.